Research programme: vitiligo therapy - BTG/King's College London

Drug Profile

Research programme: vitiligo therapy - BTG/King's College London

Alternative Names: Cyclohexylpiperine - BTG; Piperine - BTG; Piperine analogues - BTG; Tetrahydropiperine - BTG; Vitiligo therapy research programme - BTG/King's College London

Latest Information Update: 07 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG; Kings College London
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vitiligo

Most Recent Events

  • 07 May 2007 No development reported - Preclinical for Vitiligo in United Kingdom (unspecified route)
  • 05 Mar 2004 Piperine-based compounds are available for licensing (
  • 05 Mar 2004 Preclinical trials in Vitiligo in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top